Jacobio-B (01167) saw its shares rise more than 6% after the release of its annual results. At the time of writing, the stock was up 2.23%, trading at HK$6.93, with a turnover of HK$8.2854 million. On March 10, Jacobio-B announced its 2025 financial performance, reporting revenue of approximately RMB 53.5 million. Research and development expenses decreased by 42.9% year-over-year to RMB 188.6 million, while administrative expenses fell 20.2% to RMB 34.4 million. The net loss narrowed by 6.25% to about RMB 146 million. The company holds a robust patent portfolio that protects its drug candidates and technologies. As of December 31, 2025, Jacobio-B had 380 active patents or patent applications filed globally, with 146 patents granted or allowed in key international markets. During the year, the company entered into a licensing and collaboration agreement with AstraZeneca PLC to jointly develop and commercialize the pan-KRAS inhibitor JAB-23E73. Under the terms of the agreement, Beijing Jacobio is entitled to receive a $100 million upfront payment from AstraZeneca and may receive additional milestone payments upon achieving specific development, regulatory, and commercial milestones, with total potential consideration reaching up to $1.915 billion. Furthermore, if the licensed product is successfully commercialized, Beijing Jacobio will be eligible to receive tiered royalties based on the net sales of the product.